CCDRD AG offers a unique service to the pharmaceutical and biotech industry called Strategic Drug Development (SDD). The mission is to efficiently guide drug development to clinical proof of concept studies. The SDD group provides consultancy services and operational program implementation to assist you in formulating strategic and tactical decisions during the early development stage. To guide the entire process, your SDD program director acts as a single point of contact, serving as your partner in interpreting data, solving problems, strategic planning, and tailoring a program to meet your specific needs and goals.
With our SDD services, CCDRD AG links the various early drug development steps, clinical goals, planning, and implementation into a comprehensive early drug development strategy. The SDD team will identify a fast and efficient path from preclinical to early human efficacy trials by establishing a multidisciplinary team of experts in chemistry, toxicology, pharmacology, regulatory affairs, and clinical trials. Whether your goal is to launch a product globally or to outlicense it after human efficacy trials, we can develop and implement an early drug development strategy that matches your needs and timelines.
This service is supplied by BiRDS Pharma AG within the BDD/CCDRD Group service network.
CCDRD AG and partners have successfully assisted pharmaceutical companies in developing their upcoming pipelines.
Services in the field of drug development include but are not limited to
- the establishment of a solid, cost effective drug development programme.
- risk minimization
- early worldwide regulatory negotiation
- supervision of all associated projects, global project management
- NDA (New Drug Application) preparation, also eCTD (electronic Common Technical Document)
|
